NO311565B1 - Fremgangsmåte for spalting av racemisk ketamin - Google Patents
Fremgangsmåte for spalting av racemisk ketamin Download PDFInfo
- Publication number
- NO311565B1 NO311565B1 NO19985300A NO985300A NO311565B1 NO 311565 B1 NO311565 B1 NO 311565B1 NO 19985300 A NO19985300 A NO 19985300A NO 985300 A NO985300 A NO 985300A NO 311565 B1 NO311565 B1 NO 311565B1
- Authority
- NO
- Norway
- Prior art keywords
- water
- chlorophenyl
- methylaminocyclohexanone
- tartaric acid
- acetone
- Prior art date
Links
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 title claims abstract description 29
- 238000000034 method Methods 0.000 title claims abstract description 19
- 238000003776 cleavage reaction Methods 0.000 title claims description 6
- 230000007017 scission Effects 0.000 title claims description 6
- 229960003299 ketamine Drugs 0.000 title abstract description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 52
- 229910001868 water Inorganic materials 0.000 claims description 40
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 38
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 26
- 239000000203 mixture Substances 0.000 claims description 18
- 150000003892 tartrate salts Chemical class 0.000 claims description 12
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 8
- 238000006243 chemical reaction Methods 0.000 claims description 6
- 239000003513 alkali Substances 0.000 claims description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 235000002906 tartaric acid Nutrition 0.000 claims description 4
- 239000011975 tartaric acid Substances 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 3
- 238000002955 isolation Methods 0.000 claims description 3
- 150000002576 ketones Chemical class 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 238000001953 recrystallisation Methods 0.000 claims description 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 19
- 238000003756 stirring Methods 0.000 description 17
- 238000001035 drying Methods 0.000 description 12
- YQEZLKZALYSWHR-ZDUSSCGKSA-N (S)-ketamine Chemical class C=1C=CC=C(Cl)C=1[C@@]1(NC)CCCCC1=O YQEZLKZALYSWHR-ZDUSSCGKSA-N 0.000 description 10
- 229940095064 tartrate Drugs 0.000 description 10
- 239000013078 crystal Substances 0.000 description 8
- 239000002585 base Substances 0.000 description 7
- 239000001358 L(+)-tartaric acid Substances 0.000 description 6
- 235000011002 L(+)-tartaric acid Nutrition 0.000 description 6
- FEWJPZIEWOKRBE-LWMBPPNESA-N L-(+)-Tartaric acid Natural products OC(=O)[C@@H](O)[C@H](O)C(O)=O FEWJPZIEWOKRBE-LWMBPPNESA-N 0.000 description 6
- 238000009835 boiling Methods 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 239000011877 solvent mixture Substances 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- XNLICIUVMPYHGG-UHFFFAOYSA-N pentan-2-one Chemical compound CCCC(C)=O XNLICIUVMPYHGG-UHFFFAOYSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
- C07C225/20—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C221/00—Preparation of compounds containing amino groups and doubly-bound oxygen atoms bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Indole Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pyrrole Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19619665A DE19619665C2 (de) | 1996-05-15 | 1996-05-15 | Racemattrennung von Ketamin |
| PCT/EP1997/002360 WO1997043244A1 (de) | 1996-05-15 | 1997-05-07 | Racemattrennung von ketamin |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO985300D0 NO985300D0 (no) | 1998-11-13 |
| NO985300L NO985300L (no) | 1998-11-13 |
| NO311565B1 true NO311565B1 (no) | 2001-12-10 |
Family
ID=7794445
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19985300A NO311565B1 (no) | 1996-05-15 | 1998-11-13 | Fremgangsmåte for spalting av racemisk ketamin |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US6040479A (cs) |
| EP (1) | EP0918744B1 (cs) |
| JP (1) | JP4151988B2 (cs) |
| AT (1) | ATE272606T1 (cs) |
| AU (1) | AU727528B2 (cs) |
| CA (1) | CA2253575C (cs) |
| CZ (1) | CZ293546B6 (cs) |
| DE (2) | DE19619665C2 (cs) |
| DK (1) | DK0918744T3 (cs) |
| EE (1) | EE03436B1 (cs) |
| ES (1) | ES2224247T3 (cs) |
| HU (1) | HU225773B1 (cs) |
| IL (1) | IL127026A (cs) |
| NO (1) | NO311565B1 (cs) |
| PL (1) | PL187625B1 (cs) |
| PT (1) | PT918744E (cs) |
| SK (1) | SK282699B6 (cs) |
| TR (1) | TR199802317T2 (cs) |
| WO (1) | WO1997043244A1 (cs) |
| ZA (1) | ZA974216B (cs) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0002693B8 (pt) * | 2000-06-19 | 2021-05-25 | Cristalia Produtos Quim Farmaceuticos Ltda | processo de obtenção dos enantiômeros da cetamina e seus sais farmaceuticamente aceitáveis |
| SG10201802104QA (en) | 2013-03-15 | 2018-05-30 | Janssen Pharmaceutica Nv | Pharmaceutical composition of s-ketamine hydrochloride |
| US9872841B2 (en) | 2013-09-13 | 2018-01-23 | National University Corporation Chiba University | Application of R-ketamine and salt thereof as pharmaceuticals |
| KR20170040800A (ko) | 2014-08-13 | 2017-04-13 | 얀센 파마슈티카 엔.브이. | 우울증 치료 방법 |
| KR20170054470A (ko) | 2014-09-15 | 2017-05-17 | 얀센 파마슈티카 엔.브이. | VAL66MET (SNP rs6265) 유전자형 특이적 투여 계획 및 우울증 치료 방법 |
| US20160332962A1 (en) * | 2015-05-13 | 2016-11-17 | Janssen Pharmaceutica Nv | (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine |
| CA3041275A1 (en) | 2016-10-27 | 2018-05-03 | National University Corporation Chiba University | Pharmaceutical applications for (s)-norketamine and salts thereof |
| US20200009081A1 (en) | 2017-09-13 | 2020-01-09 | Janssen Pharmaceutica N.V. | Delivery Of Esketamine For The Treatment Of Depression |
| TW201919595A (zh) | 2017-09-27 | 2019-06-01 | 國立大學法人千葉大學 | 作為神經變性疾病或認知機能障礙之預防或治療劑之r-氯胺酮及其衍生物 |
| SG11202005896WA (en) | 2017-12-22 | 2020-07-29 | Janssen Pharmaceuticals Inc | Esketamine for the treatment of depression |
| CN111936127A (zh) | 2018-02-15 | 2020-11-13 | 国立大学法人千叶大学 | 炎症性疾病或骨病的预防或治疗剂及医药组合物 |
| JP2021523228A (ja) | 2018-05-04 | 2021-09-02 | パーセプション ニューロサイエンス，インコーポレイティド | 物質乱用の治療方法 |
| US20220110889A1 (en) | 2018-12-27 | 2022-04-14 | National University Corporation Chiba University | R-ketamine and derivative thereof as prophylactic or therapeutic agent for neurodevelopmental disorder |
| EP3934632A4 (en) | 2019-03-05 | 2022-11-23 | Janssen Pharmaceuticals, Inc. | Esketamine for the treatment of depression |
| WO2020212510A1 (en) * | 2019-04-16 | 2020-10-22 | Janssen Pharmaceutica Nv | Synthetic methods of preparing esketamine |
| CN112409195A (zh) * | 2020-03-17 | 2021-02-26 | 国药集团工业有限公司 | 一种(s)-氯胺酮盐酸盐的制备方法及其中间体、其晶型 |
| CN112125816A (zh) * | 2020-03-17 | 2020-12-25 | 国药集团工业有限公司 | 一种氯胺酮、其衍生物或其盐的消旋化方法 |
| WO2024145288A2 (en) * | 2022-12-28 | 2024-07-04 | Perception Neuroscience, Inc. | Methods of administering r-ketamine |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH535201A (de) * | 1969-12-19 | 1973-03-31 | Bristol Myers Co | Verfahren zur Spaltung von racemischen 2-(o-Chlorphenyl)-2-methylaminocyclohexanon in die optisch-aktiven Isomeren |
-
1996
- 1996-05-15 DE DE19619665A patent/DE19619665C2/de not_active Expired - Lifetime
-
1997
- 1997-05-07 HU HU9903085A patent/HU225773B1/hu unknown
- 1997-05-07 EP EP97923022A patent/EP0918744B1/de not_active Expired - Lifetime
- 1997-05-07 CA CA002253575A patent/CA2253575C/en not_active Expired - Lifetime
- 1997-05-07 US US09/180,530 patent/US6040479A/en not_active Expired - Lifetime
- 1997-05-07 AU AU28943/97A patent/AU727528B2/en not_active Expired
- 1997-05-07 DE DE59711834T patent/DE59711834D1/de not_active Expired - Lifetime
- 1997-05-07 WO PCT/EP1997/002360 patent/WO1997043244A1/de active IP Right Grant
- 1997-05-07 AT AT97923022T patent/ATE272606T1/de active
- 1997-05-07 DK DK97923022T patent/DK0918744T3/da active
- 1997-05-07 EE EE9800394A patent/EE03436B1/xx unknown
- 1997-05-07 SK SK1529-98A patent/SK282699B6/sk not_active IP Right Cessation
- 1997-05-07 ES ES97923022T patent/ES2224247T3/es not_active Expired - Lifetime
- 1997-05-07 PL PL97329743A patent/PL187625B1/pl unknown
- 1997-05-07 IL IL12702697A patent/IL127026A/en not_active IP Right Cessation
- 1997-05-07 PT PT97923022T patent/PT918744E/pt unknown
- 1997-05-07 CZ CZ19983558A patent/CZ293546B6/cs not_active IP Right Cessation
- 1997-05-07 JP JP54048797A patent/JP4151988B2/ja not_active Expired - Lifetime
- 1997-05-07 TR TR1998/02317T patent/TR199802317T2/xx unknown
- 1997-05-15 ZA ZA9704216A patent/ZA974216B/xx unknown
-
1998
- 1998-11-13 NO NO19985300A patent/NO311565B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| IL127026A0 (en) | 1999-09-22 |
| DE19619665A1 (de) | 1997-11-20 |
| EP0918744B1 (de) | 2004-08-04 |
| PL329743A1 (en) | 1999-04-12 |
| EP0918744A1 (de) | 1999-06-02 |
| ZA974216B (en) | 1997-12-10 |
| JP2000510135A (ja) | 2000-08-08 |
| NO985300D0 (no) | 1998-11-13 |
| PT918744E (pt) | 2004-10-29 |
| TR199802317T2 (xx) | 1999-02-22 |
| ATE272606T1 (de) | 2004-08-15 |
| NO985300L (no) | 1998-11-13 |
| ES2224247T3 (es) | 2005-03-01 |
| HUP9903085A3 (en) | 2000-05-29 |
| CZ355898A3 (cs) | 1999-04-14 |
| CA2253575C (en) | 2005-11-29 |
| DE19619665C2 (de) | 2001-03-08 |
| JP4151988B2 (ja) | 2008-09-17 |
| HUP9903085A1 (hu) | 2000-04-28 |
| AU727528B2 (en) | 2000-12-14 |
| PL187625B1 (pl) | 2004-08-31 |
| DE59711834D1 (de) | 2004-09-09 |
| AU2894397A (en) | 1997-12-05 |
| DK0918744T3 (da) | 2004-12-06 |
| SK152998A3 (en) | 1999-07-12 |
| CZ293546B6 (cs) | 2004-06-16 |
| HU225773B1 (en) | 2007-08-28 |
| CA2253575A1 (en) | 1997-11-20 |
| WO1997043244A1 (de) | 1997-11-20 |
| EE9800394A (et) | 1999-06-15 |
| SK282699B6 (sk) | 2002-11-06 |
| IL127026A (en) | 2004-02-19 |
| US6040479A (en) | 2000-03-21 |
| EE03436B1 (et) | 2001-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO311565B1 (no) | Fremgangsmåte for spalting av racemisk ketamin | |
| RU2544856C2 (ru) | НОВЫЕ ПРОИЗВОДНЫЕ 2,3,4,5-ТЕТРАГИДРО-1-ПИРИДО[4,3-b]ИНДОЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| JPS6360968A (ja) | キノリン誘導体 | |
| US20090192210A1 (en) | Polymorphs of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide | |
| US5354760A (en) | Crystalline Tiagabine monohydrate, its preparation and use | |
| US4968837A (en) | Resolution of racemic mixtures | |
| US4777291A (en) | Racemization process | |
| EP1490333B1 (en) | New atorvastatin salts and pharmaceutical compositions containing them | |
| FR2493315A1 (fr) | Derive de piperazine, procede pour sa preparation et composition analgesique en contenant | |
| AU632844B2 (en) | Halogenoalkylphenyl-alcohols, -keytones and hydrates thereof | |
| WO2016169533A1 (en) | A solid form of apremilast and a process for preparing the same | |
| HU221793B1 (hu) | Eljárás ropivakain-hidroklorid-monohidrát előállítására | |
| SK278528B6 (en) | 5-(2-methyl-4,4,4-trifluorobutylcarbamoyl)indole derivatives, preparation method thereof and pharmaceutical compositions containing them | |
| EP2358369A1 (en) | Process for the preparation of substantially optically pure repaglinide and precursors thereof | |
| WO2020234383A1 (en) | A pharmaceutical intermediate | |
| US5808088A (en) | Preparation of mibefradil via an acetamide anion | |
| US20090088590A1 (en) | Process for preparing R-gossypol L-Phenylalaninol dienamine | |
| KR100275978B1 (ko) | (-)-n-메틸-n-(4-(4-페닐-4-아세틸아미노피페리딘-1-일)-2-(3,4-디클로로페닐)부틸)벤즈아미드 및 약학적으로 허용가능한 그의 염의 제조방법 | |
| GB2341386A (en) | Synthesis of 1,4-oxazin-2-ones | |
| CN118271291B (zh) | 一种高纯度盐酸氮卓斯汀的制备方法及其应用 | |
| FR2510560A1 (fr) | Procede de preparation d'amino-4 butyramide | |
| EP0916657B9 (en) | 1-phenylpyrrolidone derivatives having optical activity | |
| NO162461B (no) | Fremgangsm te for fremstilling av aminderivater. | |
| BE565941A (cs) | ||
| JPH09268178A (ja) | 光学活性な４，５−ジフェニル−２−イミダゾリジノン誘導体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1K | Patent expired |